Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33 results about "Androgen Therapy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Administration of male hormones to produce a clinical effect.
Oral androgen therapy using modulators of testosterone bioavailability
InactiveUS20050176692A1Increase heightImprove bioavailabilityBiocideAnimal repellantsBioavailabilityFinasteride
This invention provides methods of treating a mammalian subject in need of androgen therapy by orally administering to the subject testosterone, a testosterone ester, or a testosterone precursor in an oil vehicle and by administering to the subject a modulator such as finasteride or dutasteride which increases testosterone bioavailability in the subject.
Owner:UNIV OF WASHINGTON
Oral androgen therapy using modulators of testosterone bioavailability
InactiveUS7138389B2Improve bioavailabilityRestore levelBiocideAnimal repellantsBioavailabilityFinasteride
This invention provides methods of treating a mammalian subject in need of androgen therapy by orally administering to the subject testosterone, a testosterone ester, or a testosterone precursor in an oil vehicle and by administering to the subject a modulator such as finasteride or dutasteride which increases testosterone bioavailability in the subject.
Owner:UNIV OF WASHINGTON
Polymorphs of an androgen receptor modulator
InactiveUS20070129548A1Maintain good propertiesEasy to processOrganic active ingredientsSkeletal disorderDiseaseAging skins
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
Owner:MERCK SHARP & DOHME CORP
Androgen receptor modulators and methods of use thereof
Compounds of structural formula (I) are disclosed as useful for modulating the androgen receptor (AR) in a tissue selective manner in a patient in need of such modulation, and in particular for antagonizing AR in the prostate of a male patient or in the uterus of a female patient and agonizing AR in bone and / or muscle tissue. These compounds are useful in the treating conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents. In addition, these compounds are useful as pharmaceutical composition ingredients alone and in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Diagnosis of prostate cancer
ActiveUS20060182682A1In-vivo radioactive preparationsBiological material analysisLymphatic SpreadProstate cancer
Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation.
Owner:JANSSEN BIOTECH INC
Polymorphs of an androgen receptor modulator
InactiveUS7365202B2Maintain good propertiesEasy to processOrganic active ingredientsSkeletal disorderDiseaseAging skins
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Slow release type testis prosthesis and its application
InactiveCN1947802AWith slow release functionOrganic active ingredientsSexual disorderProsthesisSilicon rubber
A slow-release artificial testis for slowly releasing androgen is prepared from silicon rubber and testosterone in weight ratio of (2-4):1. It can be used to replace human testis for androgen therapy.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1
21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
Owner:MERCK SHARP & DOHME CORP
17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators
InactiveUS20080125399A1Minimal effectReduce decreaseBiocideNervous disorderAutoimmune conditionGlucocorticoid
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Diagnosis of prostate cancer
ActiveUS8663600B2In-vivo radioactive preparationsBiological material analysisLymphatic SpreadPost operative
Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualization method, and diagnosing prostate cancer from the difference in visualization.
Owner:JANSSEN BIOTECH INC
N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators
InactiveUS20080124402A1Minimal effectReduce decreaseOrganic active ingredientsPeptide/protein ingredientsDiseaseAging skins
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Systems and methods for predicting response to anti-androgen therapy for the treatment of androgenetic alopecia
InactiveUS8758993B2Organic active ingredientsMicrobiological testing/measurementFluorescenceAnti-Androgen
Methods, processes, systems, and apparatuses are disclosed for predicting anti-androgen therapy response in the treatment of androgenetic alopecia based on a fluorometric assay and proteomics.
Owner:GLOBAL LIFE SCI PARTNERS
N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
17-Acetamido-4-azasteroid derivatives as androgen receptor modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Application of Gankyrin protein as novel molecular marker in prognosis evaluation of prostate cancer
PendingCN111596059AEffectively predict treatment prognosisDisease diagnosisStainingAntiandrogen Treatment
The invention relates to the technical field of biology, in particular to a prognosis evaluation method of a Gankyrin protein and a tumor-associated macrophage marker CD68 combined with the Gankyrin protein as a novel molecular marker in a prostate cancer pathological specimen. According to the invention, the capability of Gankyrin as a prognostic typing molecular marker in prostate cancer is verified; gankyrin and CD68 immunohistochemical staining is carried out on a prostate biopsy pathological specimen of a patient; after immunohistochemical scoring, high expression and low expression of Gankyrin and CD68 are distinguished according to corresponding truncation values; patients are divided into three groups, i.e., a high risk (high expression of Gankyrin and high expression of CD68), a medium risk (high expression of Gankyrin or high expression of CD68) and a low risk (low expression of Gankyrin and low expression of CD68), for drug resistance and transfer risk of anti-androgen therapy.
Owner:SHANGHAI CHANGHAI HOSPITAL
Systems And Methods For Predicting Response To Anti-Androgen Therapy For The Treatment Of Androgenetic Alopecia
InactiveUS20130095484A1Organic active ingredientsMicrobiological testing/measurementAntiandrogen TreatmentAnti-Androgen
Methods, processes, systems, and apparatuses are disclosed for predicting anti-androgen therapy response in the treatment of androgenetic alopecia based on a fluorometric assay and proteomics.
Owner:GLOBAL LIFE SCI PARTNERS
Application of androgen deprivation in inhibiting growth of androgen-independent tumors
PendingCN114796495AImprove treatmentGrowth inhibitionAntibody ingredientsAntineoplastic agentsTumor therapyThymus Glands
The invention relates to the technical field of tumor treatment, in particular to application of androgen deprivation in inhibiting growth of androgen-independent tumors. The invention finds that the androgen deprivation therapeutic agent can play a role in treating androgen-independent tumors by reconstructing the function of senescent thymus, and further provides a new application of the androgen deprivation therapeutic agent; the invention also finds that the androgen deprivation therapeutic agent and the immune checkpoint inhibitor can generate a synergistic effect in the treatment of the androgen-independent tumor, so that the growth of the androgen-independent tumor is more effectively inhibited, a new strategy is provided for the treatment of the androgen-independent tumor, and the application of the androgen deprivation therapeutic agent and the immune checkpoint inhibitor in the treatment of the androgen-independent tumor is promoted. A foundation is laid for expanding the application range of anti-androgen therapy, and a thought is provided for developing a new strategy of tumor immunotherapy.
Owner:北京汇睿微免科技有限公司
Methods of Treating Advanced Prostate Cancer
PendingUS20220323444A1Inhibiting and reducing growthReduce the overall heightOrganic active ingredientsPeptide/protein ingredientsSTAT5Androgen Receptor Gene
The present invention relates to methods for treatment of prostate cancer, including castrate resistant prostate cancer that resistant to at least one anti-androgen therapy. The methods include administering an effective amount of a Jak2 inhibitor which inhibits through the Stat5 pathway and is able to reduce or inhibit expression of androgen receptor in prostate cancer.
Owner:THE MEDICAL COLLEGE OF WISCONSIN INC
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
Owner:MERCK SHARP & DOHME CORP
Slow release type testis prosthesis and its application
InactiveCN100423792CWith slow release functionOrganic active ingredientsSexual disorderProsthesisSilicon rubber
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1
Repurposing Anti-Androgen Therapy for COVID-19 and Immunotherapy
PendingUS20220288029A1Increased mortalityReduce expressionImmunological disordersNitrile/isonitrile active ingredientsPharmaceutical drugOncology
Use of an AR antagonist, e.g., enzalutamide and other known AR antagonists, for reducing inflammatory genes of COVID-19 subjects is provided by the present invention. In other aspects, the present invention is directed to the use of an AR antagonist, e.g., the drug enzalutamide and other known AR antagonists, to treat lung cancer in a subject. In yet other aspects, the present invention is directed to an AR antagonist, e.g., the drug enzalutamide and other known AR antagonists, as an immunotherapy.
Owner:WISCONSIN ALUMNI RES FOUND
Diagnosis of Prostate Cancer
Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation.
Owner:JANSSEN BIOTECH INC
Diagnosis of prostate cancer
InactiveUS20160220713A1Radioactive preparation carriersImmunoglobulins against enzymesLymphatic SpreadRadiology
Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post-operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation.
Owner:JANSSEN BIOTECH INC
Fluorinated 4-azasteroids as androgen receptor modulators
InactiveUS7410977B2Minimal effectPromote growthOrganic active ingredientsPeptide/protein ingredientsDiseaseHormone Receptor Modulators
Owner:MERCK SHARP & DOHME CORP
2-hydroxy-2-phenylthiophenylpropionamides as androgen receptor modulators
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HFV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Use of androgen for treating gastrointestinal disorders
InactiveUS20170246192A1Reduce amountIncreasing testosterone levelOrganic active ingredientsPharmaceutical delivery mechanismAnabolic steroidInflammatory Bowel Diseases
By lowering the amount of Sexual Hormone Binding Globulin (SHBG) and, thereafter, raising the serum testosterone level in a person's body, an effective method for treating gastrointestinal disorders such as irritable bowel syndrome and inflammatory bowel disease, including Crohn's Disease and ulcerative colitis, is achieved. First and second androgens, namely, anabolic steroids, are used to lower the SHBG and, thereafter, raise the serum testosterone level in the body, respectively. The SHBG is lowered and the testosterone level is increased until an equilibrium between the SHBG and the second androgen is reached which normalizes the Free Androgen Index (FAI) in the person's body. Preferably, the first androgen used herein to lower the SHBG is stanozolol and the second androgen used herein to normalize the FAI is testosterone.
Owner:LICHTEN EDWARD M
Coumarin-modified androgens for the treatment of prostate cancer
Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and / or hyperplastic cells and / or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and / or hyperplastic cell growth and / or molecular imaging of malignant cells and / or hyperplastic cells and / or inducing degradation of a target protein. Also provided are compositions.
Owner:UNIV OF KENTUCKY RES FOUND +1
Salt of an androgen receptor modulator
InactiveUS20090048283A1Maintain good propertiesEasy to processBiocideNervous disorderDiseaseActive agent
The biphthalate salts of compound I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com